Hereditary breast cancer and genetic counseling in young women

Breast Cancer Research and Treatment

Volumn 123, Issue SUPPL. 1, 2010, Pages 7-9

  Brunet, Joan ^a  

^a HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; OLAPARIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM COMPLEX; PROGESTERONE RECEPTOR; PROTEIN P53;

ADJUVANT CHEMOTHERAPY; AGE DISTRIBUTION; AUTOSOMAL DOMINANT INHERITANCE; BREAST CANCER; BREAST SURGERY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COWDEN SYNDROME; DRUG RESPONSE; FAMILY HISTORY; GENE MUTATION; GENETIC COUNSELING; GENETIC DISORDER; GENETIC RISK; GENETIC SCREENING; HUMAN; ONSET AGE; PATIENT EDUCATION; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; REVIEW; TUMOR VOLUME;

EID: 77957691016     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1050-5     Document Type: Review

References (22)

1. GA Colditz WC Willett DJ Hunter MJ Stampfer JE Manson CH Hennekens, et al. 1993 Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study JAMA 270 3 338 343 1:STN:280:DyaK3szgt1SltA%3D%3D 10.1001/jama.270.3.338 8123079
2. EB Claus JM Schildkraut WD Thompson NJ Risch 1996 The genetic attributable risk of breast and ovarian cancer Cancer 77 11 2318 2324 1:STN:280:DyaK283isV2jsg%3D%3D 10.1002/(SICI)1097-0142(19960601)77:11<2318:: AID-CNCR21>3.0.CO;2-Z 8635102
3. DF Easton DT Bishop D Ford GP Crockford 1993 Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium Am J Hum Genet 52 4 678 701 1:CAS:528:DyaK2cXhtVemurs%3D 8460634
4. DF Easton D Ford DT Bishop 1995 Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium Am J Hum Genet 56 1 265 271 1:STN:280:DyaK2M7is1Whsw%3D%3D 7825587
5. R Nusbaum KJ Vogel K Ready 2006 Susceptibility to breast cancer: hereditary syndromes and low penetrance genes Breast Dis 27 21 50 17917139
6. IL Andrulis H Anton-Culver J Beck B Bove J Boyd S Buys, et al. 2002 Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations Hum Mutat 20 1 65 73 1:CAS:528:DC%2BD38XlslKrtrc%3D 10.1002/humu.10097 12112659
7. SR Young RT Pilarski T Donenberg C Shapiro LS Hammond J Miller, et al. 2009 The prevalence of BRCA1 mutations among young women with triple-negative breast cancer BMC Cancer 9 86 1:CAS:528:DC%2BD1MXjvVSitLg%3D 10.1186/1471-2407-9-86 19298662
8. DM Euhus KC Smith L Robinson A Stucky OI Olopade S Cummings, et al. 2002 Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO J Natl Cancer Inst 94 11 844 851 1:CAS:528: DC%2BD38Xlt1Sqs70%3D 12048272
9. AC Antoniou PP Pharoah P Smith DF Easton 2004 The BOADICEA model of genetic susceptibility to breast and ovarian cancer Br J Cancer 91 8 1580 1590 1:CAS:528:DC%2BD2cXotlCkur8%3D 15381934
10. WD Foulkes IM Stefansson PO Chappuis LR Begin JR Goffin N Wong, et al. 2003 Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer J Natl Cancer Inst 95 19 1482 1485 1:CAS:528:DC%2BD3sXnvVCjtrk%3D 14519755
11. WD Foulkes K Metcalfe P Sun WM Hanna HT Lynch P Ghadirian, et al. 2004 Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type Clin Cancer Res 10 6 2029 2034 1:CAS:528:DC%2BD2cXisVGlu7c%3D 10.1158/1078-0432.CCR-03-1061 15041722
12. Korde LA, Calzone KA, Zujewski J (2004) Assessing breast cancer risk: genetic factors are not the whole story. Postgrad Med 116:(4):6-8, 11-4, 19-20
13. DK Gaffney RM Brohet CM Lewis JA Holden SS Buys SL Neuhausen, et al. 1998 Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations Radiother Oncol 47 2 129 136 1:CAS:528: DyaK1cXjt1Clurk%3D 10.1016/S0167-8140(98)00023-1 9683359
14. CT Brekelmans C Seynaeve M Menke-Pluymers HT Bruggenwirth MM Tilanus-Linthorst CC Bartels, et al. 2006 Survival and prognostic factors in BRCA1-associated breast cancer Ann Oncol 17 3 391 400 1:STN:280: DC%2BD287ht1OksQ%3D%3D 10.1093/annonc/mdj095 16322115
15. Sigurdsson H, Agnarsson BA, Jonasson JG, Björnsdottir IB, Barkardottir RB, Gudlaugsdottir S et al (1996) Survival among breast cancer patients in families carrying the BRCA2 susceptibility gene. Breast Cancer Res Treat 367:33 (Abstract 1)
16. LC Verhoog CT Brekelmans C Seynaeve G Dahmen AN van Geel CC Bartels, et al. 1999 Survival in hereditary breast cancer associated with germline mutations of BRCA2 J Clin Oncol 17 11 3396 3402 1:STN:280:DC%2BD3c%2FhvVamsg%3D%3D 10550133
17. M Robson T Svahn B McCormick P Borgen CA Hudis L Norton, et al. 2005 Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series Cancer 103 1 44 51 10.1002/cncr.20728 15558796
18. Garcia-Etienne CA, Barile M, Gentilini OD, Botteri E, Rotmensz N, Sagona A et al (2009) Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer? Ann Surg Oncol
19. T Byrski T Huzarski R Dent J Gronwald D Zuziak C Cybulski, et al. 2009 Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients Breast Cancer Res Treat 115 2 359 363 1:CAS:528:DC%2BD1MXmsVGjsrs%3D 10.1007/s10549-008-0128-9 18649131
20. PO Chappuis J Goffin N Wong C Perret P Ghadirian PN Tonin, et al. 2002 A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer J Med Genet 39 8 608 610 1:STN:280:DC%2BD38vgvVKrug%3D%3D 10.1136/jmg.39.8.608 12161606
21. Tutt A, Robson M, Garber JE, Domchek S, Audeh MW, Weitzel JN, et al (2009) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol (Meeting Abstracts) 27(18S):CRA501
22. ST Vadaparampil GP Quinn C Knapp TL Malo S Friedman 2009 Factors associated with preimplantation genetic diagnosis acceptance among women concerned about hereditary breast and ovarian cancer Genet Med 11 10 757 765 10.1097/GIM.0b013e3181b3f451 19710615